Orion Announces Filing of Annual Report for the Year Ended December 31, 2015

LUXEMBOURG--(BUSINESS WIRE)-- On March 3, 2016, the Company filed its annual report for the year ended December 31, 2015 (the “2015 Annual Report”). The 2015 Annual Report contains audited consolidated financial statements, operating and financial review and other disclosure. The 2015 Annual Report was filed with the U.S. Securities and Exchange Commission on Form 20-F and is available at www.sec.gov, in the “Investor Relations” section of www.orioncarbons.com and at the Company’s registered office at 6, Route de Trèves, L-2633 Senningerberg (Municipality of Niederanven), Grand Duchy of Luxembourg.

A copy of the 2015 Annual Report may be obtained, free of charge, by contacting the Company’s Investor Relations at [email protected], by fax to +1-832-445-3335 or in writing by post to Orion Engineered Carbons S.A., 6, Route de Trèves, L-2633 Senningerberg (Municipality of Niederanven), Grand Duchy of Luxembourg.

About Orion Engineered Carbons S.A.

Orion Engineered Carbons (NYSE: OEC) is a worldwide supplier of Carbon Black. The company offers standard and high-performance products for Coatings, Printing Inks, Polymers, Rubber and other applications. Our high-quality Gas Blacks, Furnace Blacks and Specialty Carbon Blacks tint, colorize and enhance the performance of plastics, paints and coatings, inks and toners, adhesives and sealants, tires, and manufactured rubber goods such as automotive belts and hoses. With 1,530 employees worldwide, Orion Engineered Carbons runs 15 global production sites and four Applied Technology Centers. For more information visit our website www.orioncarbons.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160304005715/en/

Orion Engineered Carbons S.A.
Investor Relations
Diana Downey, +1 832 445-3865
[email protected]

Source: Orion Engineered Carbons S.A.

You May Also Be Interested In

• MoonLake prices $200 million public offering at $20 per share
• YZi Labs ends proxy fight with CEA Industries in board deal
• Silexion gets German approval for pancreatic cancer trial of SIL204